LENZ Cuts Projected 2027 Operating Expenses After VIZZ Sales Rise

The Tip Desk · November 9, 2026 · 3 min read

Third-quarter VIZZ product sales were $2.6 million on more than 38,000 paid prescriptions, up about 50% from the second quarter, after a 9% sequential gain in the prior period.

LENZ Therapeutics, Inc. (LENZ), a pharmaceutical company commercializing VIZZ, the first aceclidine-based eye drop for presbyopia, reported third-quarter product sales of $2.6 million on more than 38,000 paid prescriptions, up about 50% from the second quarter, after a 9% sequential gain in the prior period.

The company said momentum continued into the fourth quarter as consumer awareness broadened and telehealth adoption increased. In July it launched a telehealth prescribing option that bundles an online evaluation by independent licensed eye care providers, ePharmacy fulfillment and home delivery. That channel contributed more than 50% of the incremental VIZZ prescriptions in the third quarter versus the second.

Unique prescribing eye care professionals rose to more than 15,000 from launch through the third quarter, from more than 13,000 through the second quarter, with more than 75% prescribing multiple times. More than 60% of ePharmacy patients had purchased more than one monthly pack since launch, the company said, consistent with average refill rates of five packs a year among patients who started in the fourth quarter of 2025 and the first quarter of 2026.

Total revenue was $3.4 million for the three months ended September 30, 2026, versus $12.5 million a year earlier. License revenue was $0.8 million, including a portion of the upfront payment under the Arrotex license agreement, compared with $12.5 million in the same 2025 period. Product sales, net, were $2.6 million; the company had no product sales in the year-ago three months.

Selling, general and administrative expenses were $35.8 million, up from $27.6 million a year earlier, which the company attributed primarily to launch investment in commercial marketing, advertising, sales infrastructure and headcount. Research and development expenses were zero, versus $3.8 million a year earlier. Net loss widened to $31.0 million, or $0.99 a share, from $16.7 million, or $0.59 a share, in the year-ago quarter.

Cash, cash equivalents and marketable securities were $197.3 million as of September 30, 2026, down from $258.4 million as of March 31, 2026.

The company announced a strategic reorganization, implemented in the fourth quarter of 2026, to prioritize consumer marketing and support continued expansion of VIZZ. It expects the reorganization to reduce projected 2027 annualized operating expenses by more than 50%, targeting approximately $70 million to $75 million in 2027 operating expenses excluding stock-based compensation. Substantially all related activities are anticipated to be completed during the fourth quarter, with an estimated $5 million in one-time net restructuring charges.

Eef Schimmelpennink, President and Chief Executive Officer, is to transition from his role effective December 1, 2026. Dan Chevallard, the chief financial officer, was appointed Interim President and Chief Executive Officer. Schimmelpennink said he will continue as a strategic advisor into 2027.

Ex-U.S. regulatory filings advanced to eleven, including a Saudi Arabia submission under the Lunatus distribution agreement in July and Malaysia and Vietnam submissions under Lotus Pharmaceutical in August and September.

Schimmelpennink said the company is focusing commercial investment on initiatives it believes will most effectively increase consumer awareness, access and adoption while improving capital efficiency.